Teva Pharmaceutical Industries Lt.../  IL0006290147  /

Nasdaq Other OTC
2024-10-30  7:03:17 PM Chg. - Volume Bid- Ask- Market Capitalization Dividend Y. P/E Ratio
17.0000USD - 100
Turnover: 1,700
-Bid Size: - -Ask Size: - 11.7 bill.USD - -

Business description

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions to millions of patients every day. Headquartered in Israel, Teva is the world’s largest generic medicines producer, leveraging its portfolio of more than 1,800 molecules to produce a wide range of generic products in nearly every therapeutic area. In specialty medicines, Teva has a world-leading position in innovative treatments for disorders of the central nervous system, including pain, as well as a strong portfolio of respiratory products. Teva integrates its generics and specialty capabilities in its global research and development division to create new ways of addressing unmet patient needs by combining drug development capabilities with devices, services and technologies.
 

Management board & Supervisory board

CEO
Kåre Schultz
Management board
Eli Kalif, David M. Stark, Dr. Hafrun Fridriksdottir, Eli Shani, Eric Drapé, Galia Inbar, Lori Queisser, Mark Sabag, Nir Baron, Richard Daniell, Sven Dethlefs
Supervisory board
Dr. Sol J. Barer, Amir Elstein, Dr. Perry D. Nisen, Dr. Tal Zaks, Gerald M. Lieberman, Janet S. Vergis, Jean-Michel Halfon, Kåre Schultz, Nechemia J. Peres, Prof. Ronit Satchi-Fainaro, Roberto A. Mignone, Rosemary A. Crane
 

Company data

Name: Teva Pharmaceuticals Industries Ltd.
Address: 5 Basel St.,Petach Tikva 49131, Israel
Phone: +972-3-914-8171
Fax: +972-3-914-8678
E-mail: -
Internet: www.tevapharm.com
Industry: Healthcare
Sector: Pharmaceutical Industry
Sub sector: Pharmaceuticals
End of financial year: 12-31
Free Float: 88.20%
IPO date: -

Investor relations

Name: Kevin C. Mannix
IR phone: +215-591-8912
IR Fax: -
IR e-mail: kevin.mannix@tevapharm.com

Company calendar

CW 45 | 2024-11-06 Interim Report 3rd Quarter/9 Months
 

Main Shareholders